Media

Category: Press

Filter by
Press
Dipharma SA
2 October 2023

Sapropterin Dihydrochloride sachets and tablets are now available in the United Kingdom

Chiasso, Switzerland and Reading, England, October 4th, 2023 – Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”) are delighted to announce the official launch of Sapropterin Dihydrochloride (“Sapropterin”) in the United Kingdom. Sa...
Press
Dipharma SA
3 July 2023

Sapropterin Dipharma is now available in Europe and Switzerland

Chiasso, Switzerland, July 3rd, 2023 – Dipharma SA (“Dipharma”) today announced that its product Sapropterin Dipharma is now available in main European Countries and in Switzerland. Sapropterin Dipharma is available in the form of soluble ta...
Press
Dipharma SA
27 June 2023

Dipharma and LogixX Pharma announce granting of marketing authorisation approval for generic Sapropterin in United Kingdom

Chiasso, Switzerland and Reading, England, June 27, 2023 – Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”) are pleased to announce that the Medicines and Healthcare Products Regulatory Agency (“MHRA”) has granted Marketing Authorization for ...
Press
Dipharma SA
31 May 2023

Analog Pharma and Dipharma announce US FDA approval of abbreviated new drug application (ANDA) of 20 mg generic nitisinone capsules (temperature stable)

Princeton, NJ and Chiasso, Switzerland, May 31 st , 2023 – Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug applica...
Press
Dipharma SA
15 September 2022

Dipharma SA honored as one of the best companies to work for in Switzerland for 2022

Chiasso, September 15th, 2022 | Dipharma SA, a specialty pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized as one of the best places to work for in Switzerland. During the ass...
Press
Dipharma SA
21 June 2022

Analog Pharma and Dipharma announce US FDA approval of abbreviated new drug application (ANDA) of generic Nitisinone capsules (temperature stable)

Rosemont, PA and Chiasso, Switzerland, June 21st, 2022 – Analog Pharma (“Analog”) and Dipharma S.A. (“Dipharma”) today announced that their nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug ...
Press
Dipharma SA
16 February 2021

Miglustat Dipharma is now available in Switzerland

Chiasso, Switzerland, February 16th, 2021 – Swiss-based Dipharma S.A. (“Dipharma”) today announced that its proprietary product Miglustat Dipharma 100 mg capsules is now available in Switzerland. Miglustat Dipharma, a generic equivalent to Actelio...
Press
Dipharma SA
20 February 2019

Dipharma announces grant of centralised marketing authorization for generic Miglustat in Europe

Chiasso, Switzerland, February 20th, 2019 – – Dipharma S.A. (“Dipharma”) today announced that the European Commission has granted Marketing Authorization of its generic Miglustat. This authorization comes after CHMP positive opinion last December ...
Press
Dipharma SA
18 April 2018

Amerigen and Dipharma announce U.S. FDA approval for generic MIGLUSTAT 100 mg capsules

The first generic version of Miglustat is now approved in the U.S. Lyndhurst, N.J. and Chiasso, Switzerland. April 18th, 2018 – Amerigen Pharmaceuticals Limited (“Amerigen”) and Dipharma S.A. (“Dipharma”) today announced that Amerigen’s Abbr...
Press
Dipharma SA
23 February 2017

Dipharma announces the validation of DISANIT® (NITISINONE) marketing authorization application in Europe

The first stable capsule formulation of Nitisinone for the treatment of hereditary Tyrosinemia type-1 (HT-1) is now under marketing authorization (MA) evaluation in the EU. Chiasso, Switzerland, February 23rd, 2017 – Dipharma S.A. announces the va...
EnglishDeutsch